Tumor Biology

, Volume 35, Issue 5, pp 4673–4685 | Cite as

Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma

  • Spyridon Christodoulou
  • Dimitra K. Alexopoulou
  • Christos K. Kontos
  • Andreas Scorilas
  • Iordanis N. Papadopoulos
Research Article


Members of the family of tissue kallikrein and kallikrein-related peptidases possess important prognostic value in cancer. Moreover, the oncogenic role of kallikrein-related peptidase-6 (KLK6) in colorectal cancer has been well documented so far. This study investigated the prognostic value of KLK6 mRNA expression as a molecular tissue biomarker in colorectal adenocarcinoma. For this purpose, KLK6 mRNA expression was studied in 110 primary colorectal adenocarcinomas and 39 paired noncancerous colorectal specimens. A dramatic upregulation of KLK6 mRNA expression was observed in colorectal tumors. KLK6 mRNA overexpression was associated with high depth of tumor invasion, presence of distant metastases, and tumor-node-metastasis (TNM) stage of patients. Furthermore, KLK6 mRNA expression was shown to predict poor disease-free and overall survival independently of patient gender, age, tumor size, location, histological subtype, grade, venous invasion, lymphatic invasion, TNM stage, radiotherapy, and chemotherapy treatment. Moreover, Kaplan–Meier survival analysis revealed that colorectal adenocarcinoma patients with negative regional lymph nodes (N0) and those without distant metastases (M0) harboring KLK6 mRNA-positive colorectal tumors tended to relapse and die earlier than N0 and M0 patients with KLK6 mRNA-negative colorectal adenocarcinoma. Thus, KLK6 mRNA expression could be considered as an independent, unfavorable molecular prognostic biomarker in colorectal adenocarcinoma, with additional prognostic value in patients without regional or distant metastases.


Kallikreins Tumor marker Molecular tissue biomarker Colorectal cancer Colon cancer Quantitative real-time PCR 


Conflicts of interest



  1. 1.
    Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the human development index (2008–2030): a population-based study. Lancet Oncol. 2012;13:790–801.CrossRefPubMedGoogle Scholar
  2. 2.
    Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem. 2001;47:624–30.PubMedGoogle Scholar
  3. 3.
    Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313–27.CrossRefPubMedGoogle Scholar
  4. 4.
    Selby JV, Friedman GD, Quesenberry Jr CP, Weiss NS. A case–control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med. 1992;326:653–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Yousef GM, Chang A, Scorilas A, Diamandis EP. Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun. 2000;276:125–33.CrossRefPubMedGoogle Scholar
  6. 6.
    Puente XS, Sanchez LM, Overall CM, Lopez-Otin C. Human and mouse proteases: a comparative genomic approach. Nat Rev Genet. 2003;4:544–58.CrossRefPubMedGoogle Scholar
  7. 7.
    Kontos CK, Scorilas A. Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers. Clin Chem Lab Med. 2012;50:1877–91.CrossRefPubMedGoogle Scholar
  8. 8.
    Emami N, Diamandis EP. New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family. Mol Oncol. 2007;1:269–87.CrossRefPubMedGoogle Scholar
  9. 9.
    Scarisbrick IA, Radulovic M, Burda JE, et al. Kallikrein 6 is a novel molecular trigger of reactive astrogliosis. Biol Chem. 2012;393:355–67.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer. 2004;4:876–90.CrossRefPubMedGoogle Scholar
  11. 11.
    Ramsay AJ, Reid JC, Adams MN, et al. Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs). Biol Chem. 2008;389:653–68.CrossRefPubMedGoogle Scholar
  12. 12.
    Nishibori M, Mori S, Takahashi HK. Physiology and pathophysiology of proteinase-activated receptors (PARs): Par-2-mediated proliferation of colon cancer cell. J Pharmacol Sci. 2005;97:25–30.CrossRefPubMedGoogle Scholar
  13. 13.
    Gratio V, Beaufort N, Seiz L, et al. Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells. Am J Pathol. 2010;176:1452–61.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacol Rev. 2001;53:245–82.PubMedGoogle Scholar
  15. 15.
    Talieri M, Li L, Zheng Y, et al. The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. Br J Cancer. 2009;100:1659–65.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Gratio V, Loriot C, Virca GD, et al. Kallikrein-related peptidase 14 acts on proteinase-activated receptor 2 to induce signaling pathway in colon cancer cells. Am J Pathol. 2011;179:2625–36.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Kontos CK, Mavridis K, Talieri M, A S. Kallikrein-related peptidases (KLKs) in gastrointestinal cancer: mechanistic and clinical aspects. Thromb Haemost. 2013;109: doi:  10.1160/TH12-11-0791.
  18. 18.
    Alexopoulou DK, Papadopoulos IN, Scorilas A. Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer. Clin Biochem. 2013.Google Scholar
  19. 19.
    Kontos CK, Chantzis D, Papadopoulos IN, Scorilas A. Kallikrein-related peptidase 4 (KLK4) mRNA predicts short-term relapse in colorectal adenocarcinoma patients. Cancer Lett. 2013;330:106–12.CrossRefPubMedGoogle Scholar
  20. 20.
    Alexopoulou DK, Kontos CK, Christodoulou S, Papadopoulos IN, Scorilas A. Kallikrein-related peptidase-11 (KLK11) mRNA expression predicts poor disease-free and overall survival in colorectal adenocarcinoma patients. Biomark Med. 2014 (in press).Google Scholar
  21. 21.
    Henkhaus RS, Gerner EW, Ignatenko NA. Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells. Biol Chem. 2008;389:757–64.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Henkhaus RS, Roy UK, Cavallo-Medved D, Sloane BF, Gerner EW, Ignatenko NA. Caveolin-1-mediated expression and secretion of kallikrein 6 in colon cancer cells. Neoplasia. 2008;10:140–8.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Diamandis EP, Scorilas A, Fracchioli S, et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol. 2003;21:1035–43.CrossRefPubMedGoogle Scholar
  24. 24.
    Ogawa K, Utsunomiya T, Mimori K, et al. Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer. Clin Cancer Res. 2005;11:2889–93.CrossRefPubMedGoogle Scholar
  25. 25.
    Santin AD, Diamandis EP, Bellone S, et al. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. Clin Cancer Res. 2005;11:3320–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Nagahara H, Mimori K, Utsunomiya T, et al. Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer. Clin Cancer Res. 2005;11:6800–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Ghosh MC, Grass L, Soosaipillai A, Sotiropoulou G, Diamandis EP. Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. Tumour Biol. 2004;25:193–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Vandell AG, Larson N, Laxmikanthan G, et al. Protease-activated receptor dependent and independent signaling by kallikreins 1 and 6 in CNS neuron and astroglial cell lines. J Neurochem. 2008;107:855–70.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Yoon H, Radulovic M, Wu J, et al. Kallikrein 6 signals through PAR1 and PAR2 to promote neuron injury and exacerbate glutamate neurotoxicity. J Neurochem. 2013;127:283–98.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Krenzer S, Peterziel H, Mauch C, et al. Expression and function of the kallikrein-related peptidase 6 in the human melanoma microenvironment. J Investig Dermatol. 2011;131:2281–8.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Darmoul D, Gratio V, Devaud H, Laburthe M. Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem. 2004;279:20927–34.CrossRefPubMedGoogle Scholar
  32. 32.
    Darmoul D, Gratio V, Devaud H, Lehy T, Laburthe M. Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol. 2003;162:1503–13.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Heider I, Schulze B, Oswald E, Henklein P, Scheele J, Kaufmann R. Par1-type thrombin receptor stimulates migration and matrix adhesion of human colon carcinoma cells by a pkcepsilon-dependent mechanism. Oncol Res. 2004;14:475–82.PubMedGoogle Scholar
  34. 34.
    Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL. Trotti A (eds): AJCC cancer staging manual, ed 7th. New York: Springer; 2010.Google Scholar
  35. 35.
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Kheirelseid EA, Chang KH, Newell J, Kerin MJ, Miller N. Identification of endogenous control genes for normalisation of real-time quantitative PCR data in colorectal cancer. BMC Mol Biol. 2010;11:12.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Dydensborg AB, Herring E, Auclair J, Tremblay E, Beaulieu JF. Normalizing genes for quantitative RT-PCR in differentiating human intestinal epithelial cells and adenocarcinomas of the colon. Am J Physiol Gastrointest Liver Physiol. 2006;290:G1067–74.CrossRefPubMedGoogle Scholar
  38. 38.
    Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Kaplan EL, Meier P. Nonparametric observation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRefGoogle Scholar
  40. 40.
    Cox DR. Regression models and life Tables. J R Stat Soc Series B Stat Methodol. 1972;34:187–202.Google Scholar
  41. 41.
    Chung DC. The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology. 2000;119:854–65.CrossRefPubMedGoogle Scholar
  42. 42.
    Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta. 2004;1705:69–89.PubMedGoogle Scholar
  43. 43.
    Inoue Y, Yokobori T, Yokoe T, et al. Clinical significance of human kallikrein7 gene expression in colorectal cancer. Ann Surg Oncol. 2010;17:3037–42.CrossRefPubMedGoogle Scholar
  44. 44.
    Alexopoulou DK, Papadopoulos IN, Scorilas A. Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer. Clin Biochem. 2013;46:1453–61.CrossRefPubMedGoogle Scholar
  45. 45.
    Florou D, Mavridis K, Scorilas A. The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents. Tumour Biol. 2012;33:2069–78.CrossRefPubMedGoogle Scholar
  46. 46.
    Linardoutsos D, Avgeris M, Bramis J, Zografos GC, A. S: Expression analysis of kallikrein-related peptidase 4 gene (KLK4) in pancreatic cancer. In: Scorilas A (ed): 4th International symposium on kallikreins and kallikrein-related peptidases. Rhodes, Greece, 2011.Google Scholar
  47. 47.
    Ruckert F, Hennig M, Petraki CD, et al. Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma. Br J Cancer. 2008;99:1484–92.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Dlamini Z, Bhoola KD. Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma. J Clin Pathol. 2005;58:915–22.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Yousef GM, Borgono CA, White NM, et al. In silico analysis of the human kallikrein gene 6. Tumour Biol. 2004;25:282–9.CrossRefPubMedGoogle Scholar
  50. 50.
    Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. Biol Chem. 2012;393:301–17.CrossRefPubMedGoogle Scholar
  51. 51.
    Sidiropoulos M, Pampalakis G, Sotiropoulou G, Katsaros D, Diamandis EP. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. Tumour Biol. 2005;26:324–36.CrossRefPubMedGoogle Scholar
  52. 52.
    Pampalakis G, Sotiropoulou G. Multiple mechanisms underlie the aberrant expression of the human kallikrein 6 gene in breast cancer. Biol Chem. 2006;387:773–82.PubMedGoogle Scholar
  53. 53.
    Tanimoto H, Underwood LJ, Shigemasa K, Parmley TH, O’Brien TJ. Increased expression of protease m in ovarian tumors. Tumour Biol. 2001;22:11–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Kountourakis P, Psyrri A, Scorilas A, et al. Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA). Cancer Sci. 2008;99:2224–9.CrossRefPubMedGoogle Scholar
  55. 55.
    Hoffman BR, Katsaros D, Scorilas A, et al. Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. Br J Cancer. 2002;87:763–71.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Shan SJ, Scorilas A, Katsaros D, Diamandis EP. Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects. Br J Cancer. 2007;96:362–72.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    White NM, Mathews M, Yousef GM, Prizada A, Popadiuk C, Dore JJ. KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma. Br J Cancer. 2009;101:1107–13.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Diamandis EP, Yousef GM, Soosaipillai AR, Bunting P. Human kallikrein 6 (zyme/protease m/neurosin): a new serum biomarker of ovarian carcinoma. Clin Biochem. 2000;33:579–83.CrossRefPubMedGoogle Scholar
  59. 59.
    Petraki C, Dubinski W, Scorilas A, et al. Evaluation and prognostic significance of human tissue kallikrein-related peptidase 6 (KLK6) in colorectal cancer. Pathol Res Pract. 2012;208:104–8.CrossRefPubMedGoogle Scholar
  60. 60.
    Nathalie HV, Chris P, Serge G, et al. High kallikrein-related peptidase 6 in non-small cell lung cancer cells: an indicator of tumour proliferation and poor prognosis. J Cell Mol Med. 2009;13:4014–22.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Petraki CD, Gregorakis AK, Vaslamatzis MM, et al. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma. Tumour Biol. 2006;27:1–7.CrossRefPubMedGoogle Scholar
  62. 62.
    Kim JT, Song EY, Chung KS, et al. Up-regulation and clinical significance of serine protease kallikrein 6 in colon cancer. Cancer. 2011;117:2608–19.CrossRefPubMedGoogle Scholar
  63. 63.
    Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol Chem. 2010;391:505–11.CrossRefPubMedGoogle Scholar
  64. 64.
    Ohlsson L, Lindmark G, Israelsson A, et al. Lymph node tissue kallikrein-related peptidase 6 mRNA: a progression marker for colorectal cancer. Br J Cancer. 2012;107:150–7.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Kontos CK, Chantzis D, Papadopoulos IN, Scorilas A. Quantitative expression analysis and prognostic significance of KLK4 mRNA expression in colon cancer; in Schmitt M, Fritz H, Sommerhoff CP, Magdolen V (eds): 3rd International symposium on kallikreins and kallikrein-related peptidases Munich, Germany, Hieronymus Druck und Verlag, 2009, pp 86.Google Scholar
  66. 66.
    Devetzi M, Trangas T, Scorilas A, Xynopoulos D, Talieri M. Parallel overexpression and clinical significance of kallikrein-related peptidases 7 and 14 (KLK7KLK14) in colon cancer. Thromb Haemost. 2013;109:716–25.CrossRefPubMedGoogle Scholar
  67. 67.
    Talieri M, Mathioudaki K, Prezas P, et al. Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer. Thromb Haemost. 2009;101:741–7.PubMedGoogle Scholar
  68. 68.
    Feng B, Xu WB, Zheng MH, et al. Clinical significance of human kallikrein 10 gene expression in colorectal cancer and gastric cancer. J Gastroenterol Hepatol. 2006;21:1596–603.CrossRefPubMedGoogle Scholar
  69. 69.
    Talieri M, Alexopoulou DK, Scorilas A, et al. Expression analysis and clinical evaluation of kallikrein-related peptidase 10 (KLK10) in colorectal cancer. Tumour Biol. 2011;32:737–44.CrossRefPubMedGoogle Scholar
  70. 70.
    Klucky B, Mueller R, Vogt I, et al. Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration, and invasion. Cancer Res. 2007;67:8198–206.CrossRefPubMedGoogle Scholar
  71. 71.
    Oikonomopoulou K, Hansen KK, Saifeddine M, et al. Proteinase-activated receptors, targets for kallikrein signaling. J Biol Chem. 2006;281:32095–112.CrossRefPubMedGoogle Scholar
  72. 72.
    Oikonomopoulou K, Hansen KK, Saifeddine M, et al. Proteinase-mediated cell signalling: targeting proteinase-activated receptors (PARS) by kallikreins and more. Biol Chem. 2006;387:677–85.PubMedGoogle Scholar
  73. 73.
    Angelo PF, Lima AR, Alves FM, et al. Substrate specificity of human kallikrein 6: salt and glycosaminoglycan activation effects. J Biol Chem. 2006;281:3116–26.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Spyridon Christodoulou
    • 1
  • Dimitra K. Alexopoulou
    • 2
  • Christos K. Kontos
    • 2
  • Andreas Scorilas
    • 2
  • Iordanis N. Papadopoulos
    • 1
  1. 1.Fourth Surgery DepartmentUniversity General Hospital “Attikon”HaidariGreece
  2. 2.Department of Biochemistry and Molecular BiologyUniversity of AthensPanepistimiopolisGreece

Personalised recommendations